Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:110:107146.
doi: 10.1016/j.yebeh.2020.107146. Epub 2020 Jun 18.

Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients

Affiliations
Free article
Review

Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients

Georgia Montouris et al. Epilepsy Behav. 2020 Sep.
Free article

Abstract

Lennox-Gastaut syndrome (LGS) is a severe developmental epileptic encephalopathy diagnosed in childhood that persists through adolescence and into adulthood. While the characteristics of LGS in pediatric patients are well defined, including "drop attacks", interictal slow spike and wave electroencephalogram (EEG) activity, and intellectual disability, these features can evolve over time, and different EEG activities may be present in adult patients with LGS. This may result in missed diagnoses in these patients and subsequent challenges for the adequate treatment of their seizures. Based on discussions held during the LGS Transition of Care advisory board meeting and thereafter, we developed proposed diagnostic and treatment algorithms for LGS in adult patients. We highlight readily available assessments to facilitate diagnosis of LGS, based on past medical history and physical examination. The LGS diagnostic algorithm recommends that clinicians consider the occurrence of wider seizure types and abnormal EEG activities to be potentially indicative of LGS. Seizure types may include atypical absence seizures, myoclonic seizures, focal seizures, and tonic-clonic seizures, and EEG may demonstrate background slowing, focal or multifocal epileptiform discharges, and diffuse fast rhythms during sleep, among other activities. Extended EEG during sleep and video-EEG should be used in equivocal cases. Treatment of LGS in adult patients should incorporate both antiseizure drug (ASD) therapy and nonpharmacologic approaches. Frequent reassessment of patients is considered a central aspect. ASDs were categorized based on order of preference for use in the treatment of LGS; Tier 1 comprises recommended first-line ASDs, and includes valproate, clobazam, lamotrigine, rufinamide, topiramate, and cannabidiol. Other treatment options include diet, neurostimulation, and surgical approaches. Developments with the potential to improve diagnosis in the future include genetic screening, while novel ASDs and advances in neurostimulation techniques may provide valuable treatment options. These algorithms should be frequently revisited to incorporate improved techniques and therapies.

Keywords: Adult; Diagnosis; Epilepsy; Lennox–Gastaut syndrome; Transition of care; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Georgia Montouris has served on advisory boards for Eisai and SK Life Science, and has served on a safety board for UCB Pharma. Sami Aboumatar has served on advisory boards and/or has carried out consulting work for Eisai and Sunovion. David Burdette has served on advisory boards for Eisai and SK Life Science; has received speaker bureau honoraria from Eisai, Greenwich Biosciences, NeuroPace, Sunovion, and UCB Pharma; and has received research grant support from Eisai, NeuroPace, and Zogenix. Sanjeev Kothare and Ruben Kuzniecky have served on an advisory board for Eisai. William Rosenfeld has served on advisory boards for Eisai and SK Life Science; serves as a consultant for SK Life Science; has received speaker bureau honoraria from Eisai, Sunovion, and UCB Pharma; and has received research grant support from Greenwich Biosciences, Neurelis, Ovid Therapeutics, SK Life Science, Takeda, and UCB Pharma. Steve Chung has served on advisory boards for Eisai, SK Life Science, Sunovion, and UCB Pharma; has received speaker bureau honoraria from Eisai, Lundbeck, Sunovion, and UCB Pharma; and has received research grant support from SK Life Science and UCB Pharma.

Comment in

  • Therapy of Lennox-Gastaut syndrome.
    Tran L, Mikati MA. Tran L, et al. Epilepsy Behav. 2021 Feb;115:107665. doi: 10.1016/j.yebeh.2020.107665. Epub 2020 Dec 24. Epilepsy Behav. 2021. PMID: 33358312 No abstract available.

Publication types

MeSH terms

LinkOut - more resources